Laiman Xiang

2.0k total citations
27 papers, 1.6k citations indexed

About

Laiman Xiang is a scholar working on Immunology, Biotechnology and Molecular Biology. According to data from OpenAlex, Laiman Xiang has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 12 papers in Biotechnology and 10 papers in Molecular Biology. Recurrent topics in Laiman Xiang's work include Toxin Mechanisms and Immunotoxins (18 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Transgenic Plants and Applications (6 papers). Laiman Xiang is often cited by papers focused on Toxin Mechanisms and Immunotoxins (18 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Transgenic Plants and Applications (6 papers). Laiman Xiang collaborates with scholars based in United States, Switzerland and United Kingdom. Laiman Xiang's co-authors include Ira Pastan, Masanori Onda, Raffit Hassan, Robert J. Kreitman, Richard Beers, Antonina Rait, Kathleen F. Pirollo, Esther H. Chang, John E. Weldon and Wenhua Tang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Laiman Xiang

27 papers receiving 1.6k citations

Peers

Countries citing papers authored by Laiman Xiang

Since Specialization

Citations

This map shows the geographic impact of Laiman Xiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laiman Xiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laiman Xiang more than expected).

Fields of papers citing papers by Laiman Xiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laiman Xiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laiman Xiang. The network helps show where Laiman Xiang may publish in the future.

Co-authorship network of co-authors of Laiman Xiang

This figure shows the co-authorship network connecting the top 25 collaborators of Laiman Xiang. A scholar is included among the top collaborators of Laiman Xiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laiman Xiang. Laiman Xiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy 2016 ·Applied immunohistochemistry & molecular morphology ·Peter B. Illei, Christine Alewine, Marianna Zahurak, Morgan L. Cowan, Elizabeth Montgomery, Raffit Hassan, Laiman Xiang, Ira Pastan, Ronan J. Kelly	11
2	Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis 2016 ·Proceedings of the National Academy of Sciences ·Xiu Fen Liu, Laiman Xiang, Qi Zhou, Jean‐Philippe Carralot, Marco Prunotto, Gerhard Niederfellner, Ira Pastan	60
3	Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity 2016 ·Oncotarget ·Ronit Mazor, Masanori Onda, (unknown), (unknown), Laiman Xiang, Jingli Zhang, Raffit Hassan, Ira Pastan	39
4	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors 2015 ·Molecular Cancer Therapeutics ·Ronit Mazor, Jingli Zhang, Laiman Xiang, (unknown), (unknown), Richard Beers, Raffit Hassan, Ira Pastan	33
5	Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers 2014 ·Molecular Cancer Therapeutics ·Christine Alewine, Laiman Xiang, Takao Yamori, Gerhard Niederfellner, Klaus Bosslet, Ira Pastan	71
6	Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors 2013 ·Molecular Cancer Therapeutics ·Xiufen Liu, Laiman Xiang, David J. FitzGerald, Ira Pastan	13
7	Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8 2013 ·Leukemia Research ·Xiaobo Hu, Hui Wei, Laiman Xiang, Oleg Chertov, Alan S. Wayne, Tapan K. Bera, Ira Pastan	16
8	A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of the WDR85 Gene 2013 ·Journal of Biological Chemistry ·Hui Wei, Tapan K. Bera, Alan S. Wayne, Laiman Xiang, Simona Colantonio, Oleg Chertov, Ira Pastan	24
9	A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity 2012 ·Molecular Cancer Therapeutics ·John E. Weldon, Laiman Xiang, Jingli Zhang, Richard Beers, Dawn A. Walker, Masanori Onda, Raffit Hassan, Ira Pastan	77
10	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy 2012 ·Proceedings of the National Academy of Sciences ·Hui Wei, Laiman Xiang, Alan S. Wayne, Oleg Chertov, David J. FitzGerald, Tapan K. Bera, Ira Pastan	42
11	Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody 2011 ·Clinical Cancer Research ·Xing Du, Laiman Xiang, Crystal L. Mackall, Ira Pastan	19
12	Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic Fibroblasts 2011 ·Journal of Biological Chemistry ·Zhaoliang Fei, Tapan K. Bera, Xiufen Liu, Laiman Xiang, Ira Pastan	42
13	A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake 2010 ·Cancer Research ·Yujian Zhang, Johanna K. Hansen, Laiman Xiang, (unknown), Masanori Onda, Mitchell Ho, Raffit Hassan, Ira Pastan	34
14	A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice 2010 ·Journal of Immunotherapy ·Johanna K. Hansen, John E. Weldon, Laiman Xiang, Richard Beers, Masanori Onda, Ira Pastan	31
15	An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes 2008 ·Proceedings of the National Academy of Sciences ·Masanori Onda, Richard Beers, Laiman Xiang, Satoshi Nagata, Qingcheng Wang, Ira Pastan	133
16	Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies 2005 ·Clinical Cancer Research ·Tomoko Ise, Hiroshi Maeda, (unknown), Laiman Xiang, Robert J. Kreitman, Ira Pastan, Satoshi Nagata	36
17	Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels 2002 ·Molecular Medicine ·Antonina Rait, Kathleen F. Pirollo, Laiman Xiang, (unknown), Esther H. Chang	46
18	Self-Assembly of a Virus-Mimicking Nanostructure System for Efficient Tumor-Targeted Gene Delivery 2002 ·Human Gene Therapy ·Liang Xu, Peter M. Frederik, Kathleen F. Pirollo, Wenhua Tang, Antonina Rait, Laiman Xiang, (unknown), (unknown), Yuzhi Yin, Esther H. Chang	87
19	Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer 2001 ·Cancer Gene Therapy ·Antonina Rait, Kathleen F. Pirollo, Vladimir Rait, (unknown), Laiman Xiang, Esther H. Chang	21
20	Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv 2001 ·Molecular Medicine ·Liang Xu, Wenhua Tang, Chengcheng Huang, William Alexander, Laiman Xiang, Kathleen F. Pirollo, Antonina Rait, Esther H. Chang	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact